Indivior PLC represents values of innovation, integrity, and patient-focused care. The company's corporate philosophy centers around providing effective medical solutions for individuals suffering from opioid addiction. Indivior is committed to developing and delivering breakthrough treatments that help patients achieve and sustain recovery, while also addressing the societal impact of addiction. With a strong focus on research and development, the company continuously strives to improve patient outcomes and empower healthcare providers with the tools needed to combat opioid dependence. Indivior PLC's dedication to its mission and relentless pursuit of excellence make it a leading player in the pharmaceutical industry.

Indivior PLC is primarily present in multiple countries and regions around the world. The company has a strong global presence, with operations and markets in countries such as the United States, United Kingdom, Germany, Canada, France, Italy, Spain, and Australia. With its focus on developing and delivering innovative treatment solutions, Indivior PLC serves patients in these countries and regions, improving their quality of life and providing them with necessary healthcare support.

Indivior PLC has achieved several significant milestones since its establishment. The company gained regulatory approval for its ground-breaking medication, Suboxone®, which is used for the treatment of opioid dependence. Additionally, Indivior expanded its global reach and presence, establishing subsidiaries in key markets such as the United States, Canada, Australia, and Germany. The company's commitment to research and development led to the successful launch of new treatments and formulations, further enhancing patient outcomes. Indivior PLC continues to innovate and collaborate with healthcare professionals and stakeholders, aiming to address the evolving needs of individuals affected by addiction and related disorders.

Indivior PLC is a pharmaceutical company specializing in providing addiction treatment solutions. With a rich history spanning over two decades, Indivior PLC was established in 2014 as a spin-off from its parent company, Reckitt Benckiser Group. Initially focused on the development of opioid addiction treatments, Indivior PLC quickly became a leader in the field thanks to its innovative products and extensive research. Today, the company maintains a global presence, serving patients in over 40 countries. Indivior PLC's commitment to improving the lives of individuals suffering from addiction has made it a trusted name in the healthcare industry.

The main competitors of Indivior PLC in the market are Reckitt Benckiser Pharmaceuticals, Sun Pharmaceutical Industries Ltd, and Alkermes.

Indivior PLC is primarily active in the pharmaceutical industry.

The business model of Indivior PLC revolves around developing and commercializing innovative treatments for addiction disorders. As a global specialty pharmaceutical company, Indivior focuses on providing evidence-based solutions to improve the quality of life for individuals suffering from opioid dependence and related co-morbidities. By leveraging its scientific expertise, the company offers a comprehensive portfolio of products and services that cater to the needs of patients, healthcare professionals, and payers. Indivior's commitment to research and development, along with its collaborative approach, helps to address the growing global epidemic of opioid addiction and advance patient care in this critical area of healthcare.

Indivior P/E suhe on 6,89.

Indivior KUV on 1,27.

AlleAktien kvaliteediskoor ettevõttele Indivior on 5/10.

oodatud Indivior käive on 1,17 mld. USD.

oodatud Indivior kasum on 216,95 mln. USD.

Indivior PLC is a specialized pharmaceutical company based in Slough, United Kingdom. The company focuses on the development, manufacturing, and marketing of medications for addiction disorders. Its business model is based on three pillars: product portfolio, research and development, and market entry strategies. The company's product range includes a wide range of prescription drugs for the treatment of addiction disorders such as opioid dependence and alcoholism. It also works closely with leading scientific institutes and universities for continuous research and development. Indivior has a strong presence in North America and recently partnered with Alvogen to accelerate market entry into China. It also operates a comprehensive program to educate patients and medical professionals about addiction disorders and their treatment. Overall, Indivior's unique business model focuses on specialized solutions for addiction disorders and collaborations with external organizations, academic institutions, government agencies, and medical professionals to provide tailored products and services worldwide. It is a leader in addiction treatment and is expected to continue being successful by leveraging its strengths and focusing on new therapeutic options and segments.

Indivior maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Indivior jaoks arvutada või ettevõte ei maksa dividende välja.

Indivior ISIN on GB00BRS65X63.

Indivior WKN on A12FHW.

Indivior tähis on INDV.L.

Viimase 12 kuu jooksul maksis Indivior dividendi suuruses 0,07 USD . See vastab ligikaudu 0,69 % dividenditootlusele. Järgneva 12 kuu jooksul maksab Indivior tõenäoliselt dividendi summas 0,59 USD.

Indivior praegune dividenditootlus on 0,69 %.

Indivior maksab kvartaalset dividendi. See makstakse välja kuudel .

Indivior maksis viimase 5 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0,59 USD. See vastab dividenditootlusele 5,58 %.

Indivior on liigitatud sektorisse 'Tervis'.

Viimase Indivior dividendide saamiseks 29.7.2016 suuruses 0,073 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 16.6.2016.

Viimane dividendimakse toimus 29.7.2016.

Aastal 2023 maksis Indivior 0 USD dividende.

Indivior dividendid makstakse välja USD.